Mitral stenosis in a Golden Retriever dog: case report
DOI:
https://doi.org/10.26605/medvet-v19n4-7828Keywords:
echocardiography, valve malformation, atrial fibrillationAbstract
Mitral stenosis is a rare cardiac condition in dogs, typically associated with large breeds, with few reports involving Golden Retrievers. This study reports the case of a female Golden Retriever presenting with clinical signs of congestive heart failure (CHF), including tachycardia, tachypnea and muffled lung sounds. Initial management included oxygen therapy, diuretics, analgesia, and pleural drainage. Additional diagnostic tests, including radiography, electrocardiography, and echocardiography, showed cardiac remodeling, atrial dilation, atrial fibrillation, and signs of congestion. After stabilization, the treatment regimen included pimobendan, benazepril, spironolactone, and furosemide. Necropsy confirmed the diagnosis, revealing thickening and fusion of the mitral valve chordae tendineae, dilation of the left cardiac chamber, and pulmonary edema. Although mitral stenosis is more commonly observed in other breeds, this appears to be one of the first reports in a Golden Retriever. The patient’s age was consistent with previous literature, which reports early diagnosis typically between 8 weeks and 6 years. Doppler echocardiography proved to be the most effective tool for diagnosis and assessment. While clinical treatment allowed symptom control, literature emphasizes significant therapeutic limitations, with surgical intervention remaining inconsistent in outcomes. This case highlights the rarity and poor prognosis of mitral stenosis in Golden Retrievers and underscores the importance of early diagnosis and careful clinical management.Downloads
References
Arndt, J.W.; Oyama, M.A. Balloon valvuloplasty of congenital mitral stenosis. Journal of Veterinary Cardiology, 15(2): 147-151, 2013.
Atkins, C.E. et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. Journal of Veterinary Internal Medicine, 23(6): 1142–1150, 2009.
Boonpala, P. et al. Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation. BMC Veterinary Research, 19(1): 130, 2023.
Brambilla, P.G. et al. Epidemiological study of congenital heart diseases in dogs: Prevalence, popularity, and volatility throughout twenty years of clinical practice. PLoS One, 15(7): e0230160, 2020.
Coffman, M. et al. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The Benazepril Spironolactone Study (BESST). Journal of Veterinary Internal Medicine, 35(4): 1673-1687, 2021.
Corrado, G.; Klein, A.; Santarone, M. Echocardiography in atrial fibrillation. Journal of Cardiovascular Medicine, 7(7): 498-504, 2006.
Fox, P.R.; Miller, M.W.; Liu, S.K. Clinical, echocardiographic, and Doppler imaging characteristics of mitral valve stenosis in two dogs. Journal of the American Veterinary Medical Association, 201(10): 1575-1579, 1992.
Goutal, C.M. et al. Evaluation of acute congestive heart failure in dogs and cats: 145 cases (2007–2008). Journal of Veterinary Emergency and Critical Care, 20(3): 330-337, 2010.
Keene, B.W. et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine, 33(3): 1127-1140, 2019.
Lehmkuhl, L.B.; Ware, W.A.; Bonagura, J.D. Mitral stenosis in 15 dogs. Journal of Veterinary Internal Medicine, 8(1): 2-17, 1994.
Natanzon, A.; Kronzon, I. Pericardial and pleural effusions in congestive heart failure—anatomical, pathophysiologic, and clinical considerations. The American journal of the medical sciences, 338(3): 211-216, 2009.
Ogawa, M. et al. Evaluation of the association between electrocardiogram parameters and left cardiac remodeling in dogs with myxomatous mitral valve disease. Veterinary World, 15(8): 2072, 2022.
Oricco, S. et al. Lung ultrasound score in dogs and cats: A reliability study. Journal of Veterinary Internal Medicine, 38(1): 336-345, 2024.
Pariaut, R. Atrial fibrillation: current therapies. Veterinary Clinics: Small Animal Practice, 47(5): 977-988, 2017.
Pedro, B.; Fontes-Sousa, A.P.; Gelzer, A.R. Canine atrial fibrillation: Pathophysiology, epidemiology and classification. The Veterinary Journal, 265: 105548, 2020a.
Pedro, B.; Fontes-Sousa, A.P.; Gelzer, A.R. Diagnosis and management of canine atrial fibrillation. The Veterinary Journal, 265: 105549, 2020b.
Tilley, L.P. et al. Manual of Canine and Feline Cardiology. 4th ed. Missouri: Saunders, 2008. 448p.
Wess, G. et al. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. Journal of Veterinary Internal Medicine, 34(6): 2232–2241, 2020
Winter, R.L. et al. Hybrid balloon valvuloplasty for management of severe mitral stenosis in four symptomatic, adult dogs. Journal of Veterinary Cardiology, 42: 83-91, 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 José Luís de Sousa Santana, Alana Larissa Ximenes Silva, Cristiane Coelho Costa, Danielle Climaco Marques, Laecio da Silva Moura, Maria Alice Batista Araujo, Marina Pinto Sanches, Yânca Bizerra Souza, Ycaro Kylldary Macêdo, Flavio Ribeiro Alves
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
A Revista de Medicina Veterinária permite que o autor retenha os direitos de publicação sem restrições, utilizando para tal a licença Creative Commons CC BY-NC-SA 4.0.
De acordo com os termos seguintes:
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
NãoComercial — Você não pode usar o material para fins comerciais.
CompartilhaIgual — Se você remixar, transformar, ou criar a partir do material, tem de distribuir as suas contribuições sob a mesma licença que o original.
Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
